Dostarlimab for the treatment of endometrium cancer and other solid tumors
-
J. Rubio-Pérez [1] ; R. Hernández [1] ; T. Hernández [1] [2] ; B. Doger [1] [2] ; V. Casado [1] ; V. Moreno [1] [2]
-
[1] Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain
-
[2] START Madrid-FJD, EarlyPhase Clinical Trials Unit, Fundación Jiménez Díaz University Hospital, Madrid, Spain
-
- Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 57, Nº. 3, 2021, págs. 187-197
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
The use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lung cancer or melanoma. The preliminary results, particularly in endometrial cancer, show a high affinity against PD-1 with encouraging clinical activity. Here we summarize the development of this compound as well as the current preclinical and clinical data and potential future development.
